N-Alkyl_NP Urea_NP Hydroxamic_NP Acids_NP as_IN a_DT New_NP Class_NP of_IN Peptide_NP Deformylase_NP Inhibitors_NNS with_IN Antibacterial_JJ Activity_NN Peptide_NN deformylase_NN (_( PDF_NP )_) is_VBZ a_DT prokaryotic_JJ metalloenzyme_NN that_WDT is_VBZ essential_JJ for_IN bacterial_JJ growth_NN and_CC is_VBZ a_DT new_JJ target_NN for_IN the_DT development_NN of_IN antibacterial_NN agents_NNS ._SENT All_DT previously_RB reported_VBN PDF_NN inhibitors_NNS with_IN sufficient_JJ antibacterial_NN activity_NN share_NN the_DT structural_JJ feature_NN of_IN a_DT 2-substituted_JJ alkanoyl_NN at_IN the_DT P1_NP '_POS site_NN ._SENT Using_VBG a_DT combination_NN of_IN iterative_JJ parallel_JJ synthesis_NN and_CC traditional_JJ medicinal_JJ chemistry_NN ,_, we_PP have_VBP identified_VBN a_DT new_JJ class_NN of_IN PDF_NN inhibitors_NNS with_IN N-alkyl_NP urea_NN at_IN the_DT P1_NP '_POS site_NN ._SENT Compounds_NNS with_IN MICs_NP of_IN <=4_JJ mug/ml_NN against_IN gram-positive_JJ and_CC gram-negative_JJ pathogens_NNS ,_, including_VBG Staphylococcusaureus_NP ,_, Streptococcuspneumoniae_NP ,_, and_CC Haemophilusinfluenzae_NP ,_, have_VBP been_VBN identified_VBN ._SENT The_DT concentrations_NNS needed_VBN to_TO inhibit_VB 50_CD %_NN of_IN enzyme_NN activity_NN (_( IC50s_NP )_) for_IN Escherichiacoli_NP Ni-PDF_NP were_VBD <=0.1_muM, 200_CD muM_NN for_IN matrilysin_NN and_CC other_JJ mammalian_JJ metalloproteases_NNS ._SENT Structure-activity_NN relationship_NN analysis_NN identified_VBN preferred_JJ substitutions_NNS resulting_VBG in_IN improved_VBN potency_NN and_CC decreased_VBD cytotoxity_NN ._SENT One_CD of_IN the_DT compounds_NNS (_( VRC4307_NP )_) was_VBD cocrystallized_VBN with_IN PDF_NP ,_, and_CC the_DT enzyme-inhibitor_NN structure_NN was_VBD determined_VBN at_IN a_DT resolution_NN of_IN 1.7_CD A._NP This_DT structural_JJ information_NN indicated_VBD that_IN the_DT urea_NN compounds_VBZ adopt_VB a_DT binding_JJ position_NN similar_JJ to_TO that_DT previously_RB determined_VBN for_IN succinate_NN hydroxamates_NNS ._SENT Two_CD compounds_NNS ,_, VRC4232_NP and_CC VRC4307_NP ,_, displayed_VBN in_IN vivo_JJ efficacy_NN in_IN a_DT mouse_NN protection_NN assay_NN ,_, with_IN 50_CD %_NN protective_JJ doses_NNS of_IN 30.8_CD and_CC 17.9_CD mg/kg_NN of_IN body_NN weight_NN ,_, respectively_RB ._SENT These_DT N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS provide_VBP a_DT starting_VBG point_NN for_IN identifying_VBG new_JJ PDF_NN inhibitors_NNS that_WDT can_MD serve_VB as_IN antimicrobial_JJ agents_NNS ._SENT A_DT largely_RB empirical_JJ search_NN for_IN new_JJ antibiotics_NNS ,_, carried_VBD out_RP since_IN the_DT 1940s_NNS ,_, has_VBZ led_VBN to_TO an_DT impressive_JJ armamentarium_NN of_IN clinically_RB useful_JJ antibacterial_NN drugs_NNS ._SENT However_RB ,_, the_DT actual_JJ number_NN of_IN targets_NNS interfered_VBN with_IN by_IN these_DT agents_NNS is_VBZ very_RB limited_VBN ._SENT Cross-resistance_NN for_IN antibiotics_NNS ,_, resulting_VBG from_IN a_DT sharing_NN of_IN the_DT same_JJ target_NN ,_, plays_VBZ an_DT important_JJ role_NN in_IN the_DT worsening_VBG problem_NN of_IN resistance_NN ._SENT It_PP is_VBZ not_RB surprising_JJ that_IN antibacterial_NN drug_NN discovery_NN efforts_NNS are_VBP now_RB focusing_VBG on_IN identifying_VBG molecules_NNS that_WDT block_VBP different_JJ targets_NNS and_CC thus_RB can_MD inhibit_VB the_DT growth_NN of_IN resistant_JJ bacteria_NNS ._SENT Analysis_NN of_IN microbial_JJ genomes_NNS has_VBZ revealed_VBN an_DT abundance_NN of_IN novel_NN and_CC potentially_RB useful_JJ targets_NNS ,_, but_CC little_RB has_VBZ so_RB far_RB resulted_VBN from_IN this_DT much_RB heralded_VBN effort_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, many_JJ bacterial_JJ enzymes_NNS that_WDT have_VBP been_VBN well_RB characterized_VBN hold_NN promise_NN for_IN the_DT discovery_NN of_IN new_JJ antibacterial_NN drugs_NNS ._SENT One_CD such_JJ target_NN that_WDT has_VBZ recently_RB received_VBN a_DT great_JJ deal_NN of_IN attention_NN is_VBZ peptide_NN deformylase_NN (_( PDF_NP ;_: EC_NP 3.5.1.31_CD )_) ._SENT Protein_NN synthesis_NN has_VBZ proven_VBN to_TO be_VB a_DT rich_JJ source_NN of_IN targets_NNS for_IN antibacterial_NN drugs_NNS ._SENT Many_JJ of_IN the_DT known_VBN antibiotics_NNS target_NN one_CD or_CC more_JJR steps_NNS of_IN this_DT complex_JJ process_NN ,_, including_VBG the_DT aminoglycosides_NNS ,_, macrolides_NNS ,_, tetracyclines_NNS ,_, and_CC oxazolidinones_NNS ._SENT Although_IN the_DT protein-synthesizing_VBG machineries_NNS of_IN bacterial_JJ and_CC mammalian_JJ cells_NNS exhibit_VBP overall_JJ similarity_NN ,_, there_EX are_VBP sufficient_JJ differences_NNS to_TO allow_VB for_IN selective_JJ blocking_VBG of_IN the_DT process_NN in_IN bacteria_NNS ._SENT One_CD significant_JJ difference_NN is_VBZ the_DT transformylation_NN and_CC subsequent_JJ deformylation_NN of_IN the_DT initiating_VBG methionine_NN in_IN bacterial_JJ translation_NN ._SENT Unlike_IN cytosolic_JJ protein_NN synthesis_NN in_IN mammalian_JJ cells_NNS ,_, protein_NN synthesis_NN in_IN bacteria_NNS is_VBZ initiated_VBN with_IN N-formylmethionine_NP ,_, which_WDT is_VBZ generated_VBN by_IN enzymatic_JJ transformylation_NN of_IN methionyl-tRNA_NN ._SENT In_IN prokaryotes_NNS ,_, the_DT N-formylmethionine_NP of_IN the_DT nascent_JJ protein_NN is_VBZ removed_VBN by_IN the_DT sequential_JJ action_NN of_IN PDF_NP and_CC a_DT methionine_NN aminopeptidase_NN to_TO afford_VB the_DT mature_JJ protein_NN ._SENT This_DT bacterium-specific_JJ requirement_NN for_IN PDF_NN in_IN protein_NN synthesis_NN provides_VBZ a_DT rational_JJ basis_NN for_IN selectivity_NN ,_, making_VBG it_PP an_DT attractive_JJ drug_NN discovery_NN target_NN ._SENT The_DT possible_JJ use_NN of_IN PDF_NN as_IN an_DT antimicrobial_JJ target_NN was_VBD recently_RB reviewed_VBN elsewhere_RB ._SENT PDF_NP activity_NN was_VBD first_RB reported_VBN by_IN Adams_NP in_IN 1968_CD ._SENT However_RB ,_, further_JJR attempts_NNS to_TO purify_VB the_DT enzyme_NN from_IN cell_NN lysates_NNS failed_VBN because_IN the_DT activity_NN was_VBD not_RB stable_JJ ._SENT The_DT enzyme_NN was_VBD not_RB characterized_VBN further_JJR until_IN the_DT early_JJ 1990s_NNS ,_, when_WRB the_DT deformylase_NN gene_NN ,_, def_NN ,_, was_VBD cloned_VBN and_CC PDF_NP was_VBD subsequently_RB overexpressed_VBN in_IN Escherichiacoli_NP ._SENT Bacterial_JJ PDF_NN belongs_VBZ to_TO a_DT new_JJ class_NN of_IN metallohydrolases_NNS that_WDT utilize_VBP an_DT Fe2+_NP ion_NN as_IN the_DT catalytic_JJ metal_NN ion_NN ._SENT The_DT ferrous_JJ ion_NN in_IN PDF_NP is_VBZ very_RB unstable_JJ and_CC can_MD be_VB quickly_RB and_CC irreversibly_RB oxidized_VBN to_TO the_DT ferric_JJ ion_NN ,_, resulting_VBG in_IN an_DT inactive_JJ enzyme_NN ._SENT Interestingly_RB ,_, the_DT ferrous_JJ ion_NN can_MD be_VB replaced_VBN with_IN a_DT nickel_JJ ion_NN in_IN vitro_NN ,_, resulting_VBG in_IN much_RB greater_JJR enzyme_NN stability_NN with_IN little_JJ loss_NN of_IN enzyme_NN activity_NN ._SENT The_DT three-dimensional_JJ structures_NNS of_IN various_JJ PDF_NN molecules_NNS ,_, including_VBG structures_NNS of_IN enzyme-inhibitor_NN complexes_NNS ,_, have_VBP been_VBN solved_VBN and_CC published_VBN ._SENT Although_IN PDF_NP is_VBZ a_DT ferrous_JJ aminopeptidase_NN with_IN a_DT primary_JJ sequence_NN very_RB different_JJ from_IN those_DT of_IN other_JJ metalloproteases_NNS ,_, it_PP has_VBZ been_VBN noted_VBN that_IN the_DT environment_NN surrounding_VBG the_DT catalytic_JJ metal_NN ion_NN of_IN PDF_NP appears_VBZ to_TO be_VB very_RB similar_JJ to_TO the_DT active_JJ sites_NNS of_IN thermolysin_NN and_CC the_DT matrix_NN metalloproteases_NNS (_( MMPs_NP )_) ._SENT The_DT catalytic_JJ metal_NN ion_NN of_IN PDF_NP is_VBZ tetrahedrally_RB coordinated_VBN with_IN two_CD histidines_NNS from_IN the_DT conserved_VBN zinc_NN hydrolase_NN sequence_NN ,_, HEXXH_NP ,_, and_CC a_DT conserved_VBN cysteine_NN from_IN an_DT EGCLS_NP motif_NN ._SENT A_DT water_NN molecule_NN that_WDT presumably_RB hydrolyzes_VBZ the_DT amide_NN bond_NN occupies_VBZ the_DT fourth_JJ position_NN in_IN the_DT tetrahedron_NN ._SENT The_DT fact_NN that_IN PDF_NP is_VBZ a_DT metalloprotease_NN makes_VBZ the_DT enzyme_NN a_DT more_RBR attractive_JJ target_NN for_IN drug_NN discovery_NN ._SENT Metalloproteases_NNS are_VBP among_IN the_DT best_RBS studied_VBN of_IN the_DT enzyme_NN classes_NNS ,_, and_CC there_EX are_VBP excellent_JJ precedents_NNS for_IN the_DT mechanism-based_JJ design_NN of_IN their_PP$ inhibitors_NNS ._SENT In_IN the_DT last_JJ few_JJ years_NNS ,_, several_JJ classes_NNS of_IN PDF_NN inhibitors_NNS have_VBP been_VBN reported_VBN (_( ,_, -_: ,_, ,_, ,_, ,_, ,_, ,_, )_) ._SENT While_IN all_DT of_IN these_DT compounds_NNS inhibit_VBP PDF_NP activity_NN ,_, most_JJS of_IN them_PP do_VBP not_RB have_VB antibacterial_NN activity_NN ,_, presumably_RB due_JJ to_TO weak_JJ potency_NN against_IN PDF_NP and/or_CC an_DT inability_NN to_TO penetrate_VB the_DT bacterial_JJ cell_NN ._SENT It_PP is_VBZ interesting_JJ that_IN among_IN these_DT compounds_NNS ,_, those_DT for_IN which_WDT the_DT concentrations_NNS needed_VBN to_TO inhibit_VB 50_CD %_NN of_IN enzyme_NN activity_NN (_( IC50s_NP )_) (_( or_CC Kis_NP )_) were_VBD greater_JJR than_IN 1_CD muM_NN had_VBD no_DT antibacterial_NN activity_NN ._SENT Based_VBN on_IN mechanistic_JJ and_CC structural_JJ information_NN ,_, together_RB with_IN an_DT understanding_NN of_IN the_DT general_JJ principles_NNS of_IN inhibiting_VBG metalloproteases_NNS ,_, a_DT generic_JJ PDF_NN inhibitor_NN structure_NN was_VBD proposed_VBN ._SENT In_IN this_DT structure_NN ,_, X_NP represents_VBZ a_DT chelating_VBG pharmacophore_NN that_WDT will_MD be_VB the_DT major_JJ component_NN to_TO provide_VB binding_JJ energy_NN ;_: the_DT n-butyl_JJ group_NN mimics_VBZ the_DT methionine_NN side_NN chain_NN ;_: and_CC P2_NP '_POS and_CC P3_NP '_POS are_VBP regions_NNS of_IN the_DT inhibitor_NN that_WDT can_MD provide_VB additional_JJ binding_JJ energy_NN ,_, selectivity_NN ,_, and_CC favorable_JJ pharmacokinetic_JJ properties_NNS ._SENT Recently_RB ,_, actinonin_NP ,_, a_DT naturally_RB occurring_VBG antibiotic_NN that_WDT was_VBD first_RB isolated_VBN in_IN 1962_CD from_IN an_DT actinomycete_NN ,_, was_VBD shown_VBN to_TO be_VB a_DT PDF_NN inhibitor_NN ._SENT In_IN this_DT study_NN ,_, we_PP report_VBP that_IN N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS ,_, which_WDT also_RB fit_VBP this_DT generic_JJ structure_NN ,_, represent_VBP a_DT new_JJ class_NN of_IN PDF_NN inhibitors_NNS ._SENT The_DT structural_JJ characterization_NN and_CC biological_JJ evaluation_NN of_IN this_DT class_NN of_IN inhibitors_NNS are_VBP presented_VBN here_RB ._SENT FIG._NN 1_CD ._SENT |_SYM Generic_NP PDF_NP inhibitor_NN structure_NN derived_VBN from_IN the_DT transition_NN state_NN of_IN the_DT deformylation_NN reaction_NN ._SENT Generic_JJ PDF_NP inhibitor_NN structure_NN derived_VBN from_IN the_DT transition_NN state_NN of_IN the_DT deformylation_NN reaction_NN ._SENT Materials_NNS ._SENT |_SYM Actinonin_NP ,_, formate_NN dehydrogenase_NN (_( FDH_NP )_) ,_, catalase_NN ,_, and_CC NAD+_NP were_VBD obtained_VBN from_IN Sigma_NP ;_: E._NP coli_NNS Ni-PDF_NP and_CC Streptococcuspneumoniae_NP Zn-PDF_NP were_VBD overproduced_VBN and_CC purified_VBN as_IN previously_RB described_VBN ._SENT N-formylmethionine-alanine-serine_NP (_( fMAS_NP )_) and_CC thio_NN ester_NN peptide_NN Ac-ProLeuGly-S-LeuLeuGly-OC2H5_NP were_VBD obtained_VBN from_IN Bachem_NP ._SENT Matrilysin_NP (_( MMP-7_JJ )_) and_CC angiotensin-converting_JJ enzyme_NN (_( ACE_NP )_) were_VBD obtained_VBN from_IN Calbiochem_NP ._SENT Hydroxypropyl-beta-cyclodextrin_NP was_VBD purchased_VBN from_IN Aldrich_NP ._SENT All_DT other_JJ chemicals_NNS were_VBD of_IN the_DT highest_JJS commercial_JJ grade_NN ._SENT Preparation_NN of_IN N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS ._SENT |_SYM The_DT method_NN of_IN preparation_NN of_IN the_DT urea_NN compounds_NNS was_VBD recently_RB reported_JJ (_( J._NP Lewis_NP ,_, J._NP Jacobs_NP ,_, C._NP Wu_NP ,_, C._NP Hackbarth_NP ,_, W._NP Wang_NP ,_, S._NP Lopez_NP ,_, R._NP White_NP ,_, J._NP Trias_NP ,_, Z._NP Yuan_NP ,_, and_CC D._NP Patel_NP ,_, Abstr_NP ._SENT 41st_NP Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 358_CD ,_, 2001_CD )_) and_CC will_MD be_VB published_VBN elsewhere_RB ._SENT Briefly_RB ,_, the_DT urea_NN hydroxamic_JJ acids_NNS (_( compound_NN 4_CD )_) were_VBD prepared_VBN in_IN eight_CD steps_NNS from_IN commercially_RB available_JJ amino_NN acid_NN precursors_NNS as_RB outlined_VBN in_IN Fig._NN ._SENT The_DT synthetic_JJ sequence_NN used_VBN Fukuyama-Mitsunobu_NP chemistry_NN followed_VBN by_IN thiolytic_JJ deprotection_NN to_TO provide_VB N-mono-alkyl-glycine_NP methyl_NN esters_NNS (_( compound_NN 1_CD )_) ._SENT Acylation_NN of_IN N-alkyl_NP amino_NN esters_NNS with_IN excess_JJ phosgene_NN under_IN aqueous_JJ reaction_NN conditions_NNS provided_VBD N-alkyl-N-chlorocarbamoyl-glycine_JJ methyl_NN esters_NNS (_( compound_NN 2_CD )_) ,_, which_WDT were_VBD subsequently_RB acylated_JJ with_IN the_DT N-alkyl-N-chlorocarbamoyl-glycine_NP methyl_NN esters_NNS in_IN pyridine_NN to_TO produce_VB tetrasubstituted_JJ ureas_NNS (_( compound_NN 3_CD )_) ._SENT Trifluoroacetic_JJ acid_NN (_( TFA_NP )_) deprotection_NN followed_VBN by_IN coupling_NN of_IN the_DT R2_NP amine_NN with_IN PyBop_NP peptide_NN coupling_NN reagent_NN and_CC treatment_NN with_IN hydroxylamine_NN provided_VBD the_DT final_JJ product_NN ,_, urea_NN hydroxamic_JJ acid_JJ PDF_NN inhibitors_NNS (_( compound_NN 4_CD )_) ._SENT Enzyme_NN assays_NNS ._SENT |_SYM All_DT absorption_NN measurements_NNS were_VBD obtained_VBN with_IN a_DT SpectraMax_NP plate_NN reader_NN (_( Molecular_NP Devices_NPS )_) ._SENT Deformylase_NN activity_NN was_VBD assayed_VBN by_IN a_DT PDF-FDH_NP coupled_VBN assay_NN as_IN previously_RB described_VBN ._SENT Briefly_RB ,_, the_DT assay_NN was_VBD carried_VBN out_RP at_IN room_NN temperature_NN with_IN 5_CD nM_NN E._NP coli_NNS Ni-PDF_NP or_CC 10_CD nM_NN S._NP pneumoniae_NP Zn-PDF_NP in_IN a_DT buffer_NN consisting_VBG of_IN 50_CD mM_NP HEPES_NP (_( pH_NN 7.2_CD )_) ,_, 10_CD mM_NP NaCl_NP ,_, and_CC 0.2_CD mg_NN of_IN bovine_JJ serum_NN albumin/ml_NN in_IN half-area_NN 96-well_NN microtiter_NN plates_NNS (_( Corning_NP )_) ._SENT The_DT reaction_NN was_VBD initiated_VBN by_IN the_DT addition_NN of_IN a_DT reaction_NN mixture_NN of_IN 0.5_CD U_NN of_IN FDH/ml_NP ,_, 1_CD mM_NP NAD+_NP ,_, and_CC 4_CD mM_NP fMAS_NNS at_IN the_DT desired_VBN concentration_NN ._SENT To_TO determine_VB the_DT IC50s_NP of_IN the_DT desired_VBN compounds_NNS ,_, PDF_NP was_VBD preincubated_VBN for_IN 10_CD min_NN with_IN various_JJ concentrations_NNS of_IN test_NN compounds_NNS prior_RB to_TO the_DT addition_NN of_IN the_DT reaction_NN mixture_NN ._SENT The_DT initial_JJ reaction_NN velocity_NN was_VBD measured_VBN as_IN the_DT initial_JJ rate_NN of_IN increase_NN in_IN the_DT absorption_NN at_IN 340_CD nm_NN ._SENT Matrilysin_NP (_( MMP-7_JJ )_) activity_NN was_VBD assayed_VBN as_IN reported_VBN previously_RB by_IN using_VBG a_DT thio_NN ester_NN peptide_NN as_IN a_DT substrate_NN ,_, with_IN some_DT modifications_NNS ._SENT Briefly_RB ,_, 0.12_CD mug_NN of_IN MMP-7/ml_NP was_VBD preincubated_VBN at_IN room_NN temperature_NN for_IN 10_CD min_NN with_IN test_NN compounds_NNS at_IN various_JJ concentrations_NNS in_IN a_DT buffer_NN containing_VBG 50_CD mM_NP Tricine_NP (_( pH_NN 7.5_CD )_) ,_, 0.2_CD M_NP NaCl_NP ,_, 10_CD mM_NP CaCl2_NP ,_, and_CC 0.05_CD %_NN Brij_NP ._SENT The_DT reaction_NN was_VBD initiated_VBN by_IN the_DT addition_NN of_IN 0.05_CD mM_NP thio_NN ester_NN peptide_NN substrate_NN (_( Ac-ProLeuGly-S-LeuLeuGly-OC2H5_NP )_) and_CC 0.1_CD mM_NP 5,5'-dithio-bis(2-nitrobenzoic_JJ acid_NN )_) ._SENT Reaction_NN progress_NN was_VBD monitored_VBN by_IN recording_VBG the_DT increase_NN in_IN the_DT absorption_NN at_IN 405_CD nm_NN ._SENT ACE_NN activity_NN was_VBD determined_VBN with_IN a_DT 96-well_NN format_NN according_VBG to_TO the_DT procedure_NN reported_VBD by_IN Maclean_NP et_FW al._FW ._SENT The_DT hydrolysis_NN product_NN of_IN the_DT enzyme_NN reaction_NN was_VBD detected_VBN by_IN derivatization_NN with_IN o-phthaldialdehyde_NN reagent_NN (_( Pierce_NP )_) by_IN following_VBG the_DT manufacturer_NN 's_POS protocol_NN ._SENT Briefly_RB ,_, 0.03_CD U_NP of_IN ACE/ml_NP was_VBD incubated_VBN with_IN test_NN compounds_NNS at_IN different_JJ concentrations_NNS at_IN room_NN temperature_NN for_IN 10_CD min_NN in_IN a_DT buffer_NN consisting_VBG of_IN 25_CD mM_NP HEPES_NP (_( pH_NN 8.2_CD )_) and_CC 0.3_CD M_NP NaCl_NP ._SENT The_DT reaction_NN was_VBD initiated_VBN when_WRB 2_CD mM_NP substrate_NN (_( hippuryl-HisLeu_NN )_) was_VBD added_VBN to_TO the_DT mixture_NN ._SENT The_DT enzyme_NN reaction_NN was_VBD carried_VBN out_RP at_IN 35C_JJ for_IN 1_CD h._NN An_DT equal_JJ volume_NN of_IN o-phthaldialdehyde_NN reagent_NN was_VBD added_VBN ,_, and_CC the_DT reaction_NN signal_NN was_VBD detected_VBN by_IN recording_VBG the_DT change_NN in_IN fluorescence_NN at_IN excitation_NN and_CC emission_NN wavelengths_NNS of_IN 360_CD and_CC 465_CD nm_NN ,_, respectively_RB ._SENT The_DT IC50_NP was_VBD calculated_VBN with_IN the_DT following_VBG equation_NN :_: In_IN this_DT equation_NN ,_, yo_NN is_VBZ enzyme_NN activity_NN in_IN the_DT absence_NN of_IN inhibitor_NN ,_, and_CC [_SYM In_NP ]_SYM is_VBZ the_DT inhibitor_NN concentration_NN ._SENT All_DT data_NNS fitting_NN was_VBD carried_VBN out_RP by_IN using_VBG nonlinear_JJ least-squares_NNS regression_NN with_IN the_DT commercial_JJ software_NN package_NN DeltaGraph_NP 4.0_CD (_( Deltapoint_NP ,_, Inc_NP )_) ._SENT Cytotoxicity_NN assays_NNS ._SENT |_SYM The_DT cytotoxicities_NNS of_IN the_DT test_NN compounds_NNS were_VBD assessed_VBN by_IN using_VBG human_JJ K562_NP (_( ATCC_NP CCL-243_NP )_) and_CC murine_JJ P388D1_NP (_( ATCC_NP CCL-46_NP )_) leukemia_NN cell_NN lines_NNS ._SENT The_DT human_JJ cell_NN line_NN K562_NP was_VBD maintained_VBN in_IN RPMI_NP 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( Gibco_NP BRL_NP )_) and_CC 1_CD mM_NP sodium_NN pyruvate_NNS ._SENT P388D1_JJ cells_NNS were_VBD grown_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN supplemented_VBD with_IN 10_CD %_NN bovine_JJ calf_NN serum_NN (_( Gibco_NP BRL_NP )_) ._SENT The_DT assays_NNS were_VBD conducted_VBN with_IN 96-well_NN microtiter_NN plates_NNS (_( Corning_NP )_) ,_, and_CC test_NN compounds_NNS were_VBD serially_RB diluted_VBN in_IN 10_CD %_NN dimethyl_NN sulfoxide_NN ._SENT A_DT volume_NN of_IN 10_CD mul_NN of_IN each_DT dilution_NN was_VBD added_VBN to_TO wells_NNS 1_CD to_TO 11_CD in_IN each_DT row_NN ;_: well_RB 12_CD ,_, used_VBN as_IN a_DT control_NN ,_, contained_VBD 10_CD mul_NN of_IN 10_CD %_NN dimethyl_NN sulfoxide_NN solution_NN without_IN drug_NN ;_: and_CC well_RB 12H_NP contained_VBD 0.25_CD mug_NN of_IN puromycin/ml_NN as_IN a_DT no-growth_JJ control_NN ._SENT Ninety_CD microliters_NNS of_IN log-phase_JJ cells_NNS (_( 5.5_CD x_SYM 104_CD cells/ml_NN )_) was_VBD suspended_VBN in_IN the_DT appropriate_JJ assay_NN medium_NN and_CC added_VBD to_TO each_DT well_NN ._SENT The_DT cells_NNS were_VBD exposed_VBN to_TO the_DT drug_NN for_IN 3_CD days_NNS at_IN 37C_JJ in_IN the_DT presence_NN of_IN 5_CD %_NN CO2_NN ._SENT On_IN day_NN 4_CD ,_, an_DT indicator_NN solution_NN containing_VBG 1_CD mg_NN of_IN XTT/ml_NP and_CC 7.7_CD mug_NN of_IN phenazine_NN methosulfate_NN (Sigma)/ml_NN in_IN phosphate-buffered_JJ saline_NN was_VBD added_VBN to_TO each_DT well_NN ,_, and_CC the_DT suspension_NN was_VBD reincubated_VBN for_IN 4_CD h_NN under_IN the_DT same_JJ conditions_NNS ._SENT The_DT XTT_NP cleavage_NN product_NN was_VBD detected_VBN by_IN recording_VBG the_DT change_NN in_IN the_DT absorption_NN at_IN 450_CD nm_NN ,_, and_CC cell_NN growth_NN as_IN a_DT percentage_NN of_IN that_DT in_IN the_DT corresponding_JJ control_NN well_RB was_VBD used_VBN to_TO calculate_VB the_DT IC50_NN with_IN equation_NN 1_CD ._SENT Susceptibility_NN studies_NNS and_CC killing_VBG curves_NNS ._SENT |_SYM Bacteria_NP used_VBN in_IN these_DT studies_NNS were_VBD stored_VBN at_IN -80C_NN and_CC grown_VBN at_IN 35C_JJ in_IN accordance_NN with_IN NCCLS_NP recommendations_NNS ._SENT For_IN susceptibility_NN tests_NNS ,_, MICs_NP were_VBD determined_VBN by_IN the_DT broth_NN microdilution_NN method_NN in_IN accordance_NN with_IN NCCLS_NP guidelines_NNS but_CC with_IN the_DT following_VBG modification_NN ._SENT Because_IN of_IN the_DT high_JJ frequency_NN of_IN resistance_NN previously_RB reported_VBD with_IN other_JJ PDF_NN inhibitors_NNS ,_, a_DT modified_JJ bacterial_JJ inoculum_NN size_NN of_IN 0.5_CD x_NN 105_CD to_TO 1.0_CD x_SYM 105_CD CFU/ml_NP was_VBD used_VBN to_TO determine_VB the_DT relative_JJ activities_NNS of_IN the_DT compounds_NNS ._SENT The_DT organisms_NNS used_VBN are_VBP all_DT part_NN of_IN the_DT Versicor_NP strain_NN collection_NN ._SENT The_DT MIC_NN was_VBD defined_VBN as_IN the_DT lowest_JJS concentration_NN that_WDT yielded_VBD no_DT visible_JJ growth_NN after_IN 24_CD h_NN of_IN incubation_NN at_IN 35C_JJ ;_: end_NN points_NNS were_VBD obtained_VBN by_IN measuring_VBG the_DT optical_JJ density_NN at_IN 600_CD nm_NN (_( OD600_NP )_) ._SENT Minimum_JJ bactericidal_JJ concentrations_NNS (_( MBCs_NP )_) were_VBD determined_VBN for_IN Haemophilusinfluenzae_NP (_( ATCC_NP 31517_CD ;_: VHIN1004_NP )_) and_CC S._NP pneumoniae_NP (_( ATCC_NP 49219_CD ;_: VSPN1001_NP )_) ._SENT The_DT MBC_NP was_VBD defined_VBN as_IN the_DT lowest_JJS concentration_NN of_IN antibiotic_NN that_WDT resulted_VBD in_IN a_DT >=3-log10_JJ decrease_NN in_IN the_DT bacterial_JJ titer_NN ._SENT Time-kill_NN curves_NNS were_VBD determined_VBN by_IN using_VBG log-phase_NN cultures_NNS of_IN H._NP influenzae_NP (_( ATCC_NP 31517_CD )_) ,_, S._NP pneumoniae_NP (_( ATCC_NP 49219_CD )_) ,_, and_CC Staphylococcusaureus_NP (_( ATCC_NP 25923_CD ;_: VSAU1003_NP )_) ._SENT The_DT bacteria_NNS were_VBD exposed_VBN to_TO 5_CD or_CC 10_CD times_NNS the_DT MIC_NN of_IN each_DT compound_NN tested_VBD ._SENT Cultures_NNS were_VBD incubated_VBN at_IN 35C_JJ ,_, and_CC titers_NNS were_VBD quantitatively_RB determined_VBN at_IN 0_CD ,_, 2_CD ,_, 6_CD ,_, 8_CD ,_, and_CC 24_CD h_NN of_IN incubation_NN ._SENT Results_NNS were_VBD expressed_VBN as_IN log10_NP CFU_NP per_IN milliliter_NN versus_CC time_NN ._SENT Expression_NN and_CC purification_NN of_IN E._NP coli_NNS PDF_NN used_VBN for_IN crystallographic_JJ studies_NNS ._SENT |_SYM The_DT E._NP colidef_NN gene_NN was_VBD cloned_VBN for_IN overexpression_NN in_IN E._NP coli_NNS BL21(DE3)/pLysS_NP as_RB described_VBD previously_RB ._SENT Fermentation_NN was_VBD performed_VBN by_IN using_VBG a_DT Bioflo_NP 2000_CD fermentor_NN (_( New_NP Brunswick_NP Scientific_NP )_) with_IN an_DT on-demand_NN fed-batch_NN strategy_NN and_CC minimal_JJ medium_NN ._SENT A_DT 4-liter_JJ fermentation_NN was_VBD maintained_VBN at_IN 37C_JJ until_IN the_DT culture_NN reached_VBD an_DT OD600_NN of_IN similar8.9_NN ._SENT The_DT temperature_NN was_VBD then_RB lowered_VBN to_TO 18C_NP ,_, and_CC the_DT culture_NN was_VBD induced_VBN overnight_RB with_IN isopropyl-beta-d-galactopyranoside_NN (_( IPTG_NP )_) at_IN a_DT final_JJ concentration_NN of_IN 0.4_CD mM_NNS ._SENT The_DT bacterial_JJ cells_NNS (_( final_JJ OD600_NN ,_, similar40_NP )_) were_VBD harvested_VBN by_IN centrifugation_NN and_CC yielded_VBD similar240_JJ g_NN of_IN paste_NN (_( wet_JJ weight_NN )_) ._SENT The_DT cells_NNS were_VBD frozen_VBN as_IN pellets_NNS and_CC stored_VBN at_IN -80C_NN ._SENT All_DT purification_NN steps_NNS were_VBD performed_VBN at_IN 4C_JJ unless_IN noted_VBN otherwise_RB ._SENT Aliquots_NNS of_IN cells_NNS (_( similar50_JJ g_NN )_) were_VBD thawed_VBN briefly_RB at_IN 37C_JJ and_CC resuspended_JJ in_IN 250_CD ml_NN of_IN lysis_NN buffer_NN (_( 20_CD mM_NP morpholineethanesulfonic_JJ acid_NN [_SYM MES]-KOH_NP [_SYM pH_NN 6.5_CD ]_SYM ,_, 100_CD mM_NP KCl_NP ,_, 5_CD mM_NP NiSO4_NP ,_, 5_CD mM_NP MgSO4_NP ,_, 10_CD mug_NN of_IN catalase/ml_NN ,_, 100_CD muM_NN phenylmethylsulfonyl_NN fluoride_NN ,_, 10.0_CD mug_NN of_IN DNase_NP I/ml_NP ,_, five_CD tablets_NNS of_IN complete_JJ protease_NN inhibitor_NN cocktail_NN without_IN EDTA_NP [_SYM Boehringer_NP Mannheim_NP ]_SYM )_) ._SENT The_DT cells_NNS were_VBD lysed_VBN with_IN four_CD freeze-thaw_NN cycles_NNS and_CC then_RB sonicated_JJ (_( four_CD 10-s_JJ bursts_NNS ,_, full_JJ power_NN )_) with_IN a_DT Virsonic_JJ 60_CD apparatus_NN (_( Virtus_NP )_) equipped_VBD with_IN a_DT titanium_NN horn_NN ._SENT The_DT pellets_NNS were_VBD collected_VBN at_IN 35,000_CD x_NN g_NN and_CC washed_VBN by_IN resuspension_NN in_IN 120_CD ml_NN of_IN lysis_NN buffer_NN ._SENT The_DT supernatants_NNS were_VBD combined_VBN and_CC clarified_VBN by_IN centrifugation_NN at_IN 100,000_CD x_NN g_NN for_IN 30_CD min_NN ._SENT DNA_NP was_VBD removed_VBN by_IN centrifugation_NN at_IN 35,000_CD x_NN g_NN following_VBG a_DT 15-min_JJ treatment_NN with_IN 0.1_CD %_NN polyethyleneimine_NN (_( final_JJ concentration_NN )_) ._SENT The_DT supernatant_JJ was_VBD buffer_NN exchanged_VBN with_IN diafiltration_NN against_IN a_DT 5-kDa-cutoff_NN membrane_NN in_IN 20_CD mM_NP morpholinepropanesulfonic_JJ acid_NN (MOPS)-KOH_NN (_( pH_NN 7.7)-50_NP mM_NP KCl-1_NP mM_NP NiSO4_NP and_CC filtered_VBN through_IN a_DT 0.2-mum-pore-size_JJ filter_NN ._SENT The_DT sample_NN was_VBD then_RB loaded_VBN at_IN a_DT flow_NN rate_NN of_IN 30_CD ml/min_NN onto_IN a_DT POROS_NP 20HQ_NP (_( perfusion_NN chromatography_NN medium_NN ;_: PE_NP Biosystems_NP )_) column_NN (_( 2_CD by_IN 16_CD cm_NN )_) equilibrated_VBN with_IN 20_CD mM_NP MOPS-KOH_NP (_( pH_NN 7.7)-1_NP mM_NP NiSO4_NP at_IN room_NN temperature_NN ._SENT A_DT linear_JJ salt_NN gradient_NN ,_, 0_CD to_TO 300_CD mM_NP KCl_NP in_IN 20_CD column_NN volumes_NNS ,_, was_VBD used_VBN to_TO elute_VB bound_JJ proteins_NNS ,_, and_CC the_DT fractions_NNS were_VBD immediately_RB placed_VBN at_IN 4C_JJ ._SENT Fractions_NNS containing_VBG Ni-PDF_NP were_VBD identified_VBN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN analysis_NN ,_, pooled_VBN ,_, and_CC further_RBR purified_VBD by_IN size_NN exclusion_NN chromatography_NN on_IN a_DT Superdex_NP 75_CD HiLoad_NN (_( 16/60_CD )_) column_NN (_( Amersham_NP Pharmacia_NP Biotech_NP )_) equilibrated_VBD with_IN 20_CD mM_NP MOPS-KOH_NP (_( pH_NN 7.7)-100_NP mM_NP KCl_NP at_IN a_DT flow_NN rate_NN of_IN 1_CD ml/min_NN ._SENT Proteins_NNS were_VBD pooled_VBN and_CC concentrated_VBN to_TO similar5_NN to_TO 10_CD mg/ml_NN ._SENT After_IN the_DT addition_NN of_IN glycerol_NN to_TO 10_CD %_NN and_CC 1_CD mM_NP Tris-(2-carboxyethyl)-phosphine_NP (_( TCEP_NP )_) hydrochloride_NN ,_, the_DT enzyme_NN was_VBD stored_VBN at_IN -80C_NN ._SENT The_DT protein_NN concentration_NN was_VBD determined_VBN with_IN Bradford_NP reagent_NN (_( Bio-Rad_NP )_) and_CC bovine_JJ serum_NN albumin_NN as_IN a_DT standard_NN ._SENT This_DT highly_RB purified_VBN Ni-PDF_NP was_VBD used_VBN directly_RB for_IN crystallization_NN ._SENT Crystallization_NN and_CC structure_NN determination_NN ._SENT |_SYM An_DT enzyme-inhibitor_NN complex_NN was_VBD formed_VBN by_IN incubation_NN of_IN a_DT twofold_JJ molar_JJ excess_NN of_IN PDF_NN inhibitor_NN VRC4307_JJ with_IN 1.5_CD mg_NN of_IN PDF/ml_NP in_IN binding_VBG buffer_NN (_( 20_CD mM_NP HEPES_NP [_SYM pH_NN 7.5_CD ]_SYM ,_, 100_CD mM_NP NaCl_NP ,_, 0.5_CD mM_NP TCEP_NNS )_) for_IN 30_CD min_NN at_IN room_NN temperature_NN ._SENT The_DT complex_NN was_VBD buffer_JJR exchanged_VBD four_CD times_NNS in_IN binding_JJ buffer_NN with_IN 50_CD muM_NN compound_NN VRC4307_JJ by_IN using_VBG a_DT Millipore_NP concentrator_NN (_( 5,000-molecular-weight_JJ cutoff_NN )_) and_CC finally_RB concentrated_VBD to_TO 36_CD mg/ml_NN ._SENT Crystals_NNS were_VBD grown_VBN by_IN the_DT hanging-drop_NN vapor_NN diffusion_NN method_NN by_IN mixing_VBG equal_JJ volumes_NNS of_IN protein_NN solution_NN and_CC well_RB buffer_NN [_SYM 100_CD mM_NP HEPES_NP (_( pH_NN 7.0_CD )_) ,_, 2.0_CD M_NP (NH4)2SO4_NP ]_SYM at_IN 17C_NP ._SENT Crystals_NNS were_VBD cryoprotected_JJ at_IN room_NN temperature_NN by_IN a_DT 15-min_JJ ,_, 10-step_JJ transfer_NN to_TO cryobuffer_NN solution_NN [_SYM 100_CD mM_NP HEPES_NP (_( pH_NN 7.0_CD )_) ,_, 2.4_CD M_NP (NH4)2SO4_NN ,_, 25_CD %_NN glycerol_NN ]_SYM with_IN 5_CD muM_NN compound_NN VRC4307_JJ and_CC immediately_RB flash-frozen_JJ in_IN a_DT 100_CD K_NP nitrogen_NN gas_NN cold_JJ stream_NN (_( model_NN 700_CD apparatus_NN ;_: Oxford_NP Cryosystems_NP )_) for_IN data_NN collection_NN ._SENT Diffraction_NN data_NNS were_VBD collected_VBN by_IN using_VBG an_DT R-AXIS-IIc_JJ image-plate_NN system_NN (_( Molecular_NP Structures_NP Corp._NP [_SYM MSC_NP ]_SYM )_) with_IN Osmic_NP Confocal_NP Max-Flux_NP optics_NNS (_( Blue-3_NP configuration_NN ;_: Rigaku/MSC_NP )_) and_CC an_DT RU-2HR_NP generator_NN (_( MSC_NP )_) operating_VBG at_IN 100_CD mA_NNS and_CC 50_CD kV_NN ._SENT A_DT complete_JJ data_NNS set_VBN was_VBD collected_VBN from_IN a_DT single_JJ crystal_NN (_( 0.2_CD by_IN 0.18_CD by_IN 0.06_CD mm_NN )_) maintained_VBN at_IN 100_CD K._NP The_DT images_NNS were_VBD indexed_VBN ,_, and_CC integration_NN was_VBD performed_VBN by_IN using_VBG Denzo/Scalepack_NP ._SENT The_DT structure_NN of_IN the_DT enzyme_NN or_CC enzyme_NN complex_NN was_VBD determined_VBN by_IN molecular_JJ replacement_NN with_IN AMoRe_NP as_RB implemented_VBD in_IN the_DT CCP4_NP package_NN with_IN a_DT structure_NN of_IN E._NP coli_NNS PDF_NN (_( e.g._FW ,_, 1ICJ_NP )_) as_IN a_DT search_NN model_NN ._SENT The_DT structure_NN was_VBD refined_VBN with_IN the_DT CNX_NP 2000_CD package_NN (_( Accelrys_NP Inc._NP )_) ._SENT Isolation_NN of_IN resistant_JJ mutants_NNS of_IN H._NP influenzae_NP and_CC S._NP pneumoniae_NNS ._SENT |_SYM Spontaneous_JJ resistant_JJ mutants_NNS were_VBD selected_VBN as_IN previously_RB described_VBN ._SENT Briefly_RB ,_, 1010_CD CFU_NP of_IN H._NP influenzae_NP (_( ATCC_NP 31517_CD )_) were_VBD plated_VBN on_IN chocolate_JJ agar_NN plates_NNS containing_VBG 30_CD mug_NN of_IN antibiotic/ml_NN ._SENT In_IN a_DT second_JJ experiment_NN ,_, approximately_RB 1010_CD CFU_NN of_IN log-phase_JJ S._NP pneumoniae_NNS (_( ATCC_NP 49219_CD )_) were_VBD spread_VBN on_IN tryptic_JJ soy_NN agar_NN (TSA)-5_NN %_NN sheep_NN blood_NN agar_NN plates_NNS containing_VBG 30_CD mug_NN of_IN test_NN compound/ml_NN ._SENT The_DT plates_NNS were_VBD incubated_VBN for_IN 48_CD h_NN at_IN 35C_JJ in_IN a_DT 10_CD %_NN CO2_JJ atmosphere_NN ._SENT Colonies_NNS were_VBD picked_VBN and_CC transferred_VBN to_TO drug-free_JJ plates_NNS ;_: stable_JJ mutants_NNS that_WDT survived_VBD this_DT passage_NN were_VBD subjected_VBN to_TO further_JJR characterization_NN ._SENT Molecular_JJ techniques_NNS and_CC sequence_NN analysis_NN ._SENT |_SYM Primary_NP sequences_NNS for_IN the_DT def_NN and_CC fmt_NN homologs_NNS of_IN H._NP influenzae_NP and_CC S._NP pneumoniae_NNS were_VBD obtained_VBN from_IN public_JJ sequence_NN databases_NNS and_CC previously_RB published_VBN work_NN ._SENT The_DT def-fmt_NN operon_NN and_CC flanking_VBG DNA_NN (_( 230_CD bp_NN upstream_JJ ;_: 60_CD bp_NN downstream_JJ )_) from_IN wild-type_NN H._NP influenzae_NP VHIN1004_NP and_CC a_DT single_JJ PDF_NN inhibitor-resistant_NN derivative_NN were_VBD amplified_VBN by_IN PCR_NP with_IN respective_JJ upstream_JJ and_CC downstream_JJ primers_NNS oPV743_NN (_( 5'-CGCCAGGTTACCAAATACTTATCTAAG-3_NP '_POS )_) and_CC oPV378_NP (_( 5'-TTTTCCGCTATAAATTTACCG-3_NP '_POS )_) for_IN def_NN and_CC oPV177_JJ (_( 5'-GCCAGCGCATTAAAGAAAAGTTG-3_JJ '_'' )_) and_CC oPV179_NP (_( 5'-CGAAAGTGCGGTCATTTTTACTG-3_NP '_POS )_) for_IN fmt_NN ._SENT The_DT defA_NN ,_, defB_NN ,_, and_CC fmt_NN genes_NNS and_CC flanking_VBG DNAs_NP (_( approximately_RB 120_CD ,_, 350_CD ,_, and_CC 60_CD bp_NN upstream_RB ,_, respectively_RB ;_: 60_CD bp_NN downstream_JJ for_IN all_DT three_CD )_) from_IN wild-type_JJ S._NP pneumoniae_NNS ATCC_NP 49619_CD and_CC two_CD PDF_NN inhibitor-resistant_NN derivatives_NNS were_VBD amplified_VBN by_IN PCR_NP with_IN the_DT respective_JJ upstream_JJ and_CC downstream_JJ primers_NNS oPV369_NN (_( 5'-CGTGGCTTGGAAGTAACT-3_NP '_POS )_) and_CC oPV370_NP (_( 5'-GATATACCAGGTCGTTGC-3_NP '_POS )_) for_IN defA_NN ,_, oPV385_NP (_( 5'-TCCCTTATTGCTCCACTTG-3_NP '_POS )_) and_CC oPV368_NP (_( 5'-TATCATTTGTTTTCATGCCTC-3_NP '_POS )_) for_IN defB_NN ,_, and_CC oPV383_JJ (_( 5'-CCACAACCTCTATCATTACCAG-3_JJ '_'' )_) and_CC oPV384_NP (_( 5'-ACCGTTCCATAGACCAGC-3_NP '_POS )_) for_IN fmt_NN ._SENT All_DT PCR_NP products_NNS were_VBD purified_VBN with_IN QiaQuick_NP DNA_NP purification_NN columns_NNS (_( Qiagen_NP )_) ,_, and_CC DNA_NN sequences_NNS were_VBD determined_VBN by_IN the_DT dideoxy_JJ chain_NN termination_NN method_NN (_( Sequetech_NP )_) ._SENT In_IN all_DT instances_NNS ,_, mutations_NNS were_VBD confirmed_VBN by_IN analysis_NN of_IN a_DT second_JJ independent_JJ PCR_NP product_NN ._SENT Pharmacokinetic_JJ studies_NNS ._SENT |_SYM CD-1_NP female_JJ outbred_VBN mice_NNS (_( Charles_NP River_NP Laboratories_NPS )_) were_VBD used_VBN for_IN pharmacokinetic_JJ analyses_NNS of_IN selected_JJ PDF_NN inhibitors_NNS ._SENT The_DT compounds_NNS were_VBD formulated_VBN in_IN 20_CD %_NN cyclodextrin_NN (_( Aldrich_NP )_) and_CC filter_VB sterilized_VBN ._SENT After_IN 1_CD week_NN of_IN acclimation_NN ,_, mice_NNS (_( 20_CD to_TO 25_CD g_NN each_DT )_) were_VBD dosed_VBN either_CC intravenously_RB (_( i.v._NP )_) or_CC orally_RB (_( p.o._JJ )_) with_IN antibiotic_NN ;_: at_IN 0.083_CD ,_, 0.25_CD ,_, 0.5_CD ,_, 1_CD ,_, 2_CD ,_, and_CC 4_CD h_NN after_IN dosing_VBG ,_, blood_NN samples_NNS were_VBD collected_VBN from_IN anesthetized_VBN mice_NNS via_IN cardiac_JJ puncture_NN ._SENT Groups_NNS of_IN four_CD mice_NNS were_VBD used_VBN for_IN each_DT time_NN point_NN ._SENT The_DT blood_NN was_VBD allowed_VBN to_TO clot_VB ,_, and_CC the_DT serum_NN samples_NNS were_VBD stored_VBN immediately_RB at_IN -80C_NN ._SENT Serum_NP was_VBD extracted_VBN with_IN a_DT mixture_NN of_IN acetonitrile_NN ,_, ethanol_NN ,_, and_CC acetic_JJ acid_NN and_CC analyzed_VBD by_IN liquid_JJ chromatography_NN with_IN triple_JJ quadropole_NN mass_NN spectrometry_NN (_( LC-MS/MS_NP )_) MS_NP (_( Phenomenex_NP LUNA-C8_NP ,_, 50_CD by_IN 2_CD mm_NN ,_, 3_CD mum_NN ,_, HP1100_NP ,_, Micromass_NP Quattro_NP LC_NP )_) with_IN an_DT internal_JJ standard_NN ._SENT The_DT pharmacokinetic_JJ parameters_NNS ,_, including_VBG Tmax_NP (_( time_NN to_TO maximum_JJ concentration_NN )_) ,_, Cmax_NP (_( maximum_JJ concentration_NN measured_VBN )_) ,_, t1/2_JJ (_( terminal_JJ half-life_NN )_) ,_, and_CC AUC_NP (_( area_NN under_IN the_DT curve_NN )_) ,_, were_VBD calculated_VBN ._SENT The_DT p.o._JJ bioavailability_NN was_VBD calculated_VBN as_IN the_DT ratio_NN of_IN the_DT AUC_NP for_IN p.o._JJ administration_NN to_TO the_DT AUC_NN for_IN i.v._JJ administration_NN ._SENT Metabolic_JJ stability_NN in_IN liver_NN microsomes_NNS ._SENT |_SYM Preparations_NNS of_IN hepatic_JJ microsomes_NNS from_IN male_JJ CD-1_JJ mice_NNS ,_, male_JJ Sprague-Dawley_NP rats_NNS ,_, and_CC human_JJ donors_NNS were_VBD obtained_VBN from_IN Xenotech_NP LLC_NP ._SENT To_TO assess_VB their_PP$ metabolic_JJ stability_NN ,_, test_NN compounds_NNS (_( 1_CD muM_NN )_) in_IN phosphate_NN buffer_NN (_( 100_CD mM_NP ,_, pH_NN 7.4_CD )_) were_VBD incubated_VBN at_IN 37C_JJ with_IN liver_JJR microsomal_JJ proteins_NNS (_( 0.2_CD mg/ml_NN )_) supplemented_VBN with_IN NADPH_NP (_( 1_CD mM_NNS )_) ,_, UDP-glucuronic_JJ acid_NN (_( 4_CD mM_NNS )_) ,_, and_CC alamethecin_NN (_( 60_CD mug/mg_NN of_IN protein_NN )_) for_IN 0_CD ,_, 10_CD ,_, 20_CD ,_, and_CC 30_CD min_NN ._SENT Aliquots_NNS were_VBD removed_VBN at_IN various_JJ times_NNS ,_, and_CC the_DT reaction_NN was_VBD terminated_VBN by_IN the_DT addition_NN of_IN acetonitrile_NN ._SENT Loss_NN of_IN the_DT parent_NN compound_NN was_VBD monitored_VBN by_IN LC-MS/MS_NP (_( PE-SCIEX_NP API3000_NP ;_: triple_JJ quadrupole_NN )_) with_IN reverse-phase_JJ high-pressure_JJ liquid_JJ chromatography_NN separation_NN (_( Phenomenex_NP LUNA-C18_NP ,_, 2.1_CD by_IN 30_CD mm_NN ,_, 3_CD mum_NN )_) ._SENT The_DT viability_NN and_CC activity_NN of_IN the_DT microsomal_JJ preparations_NNS were_VBD separately_RB verified_VBN by_IN using_VBG a_DT positive_JJ metabolic_JJ control_NN ._SENT Intrinsic_JJ clearance_NN was_VBD calculated_VBN from_IN the_DT slope_NN of_IN the_DT curve_NN of_IN log10_JJ linear_JJ concentration_NN versus_CC incubation_NN time_NN ._SENT Metabolite_NN identification_NN ._SENT |_SYM Mouse_NP serum_NN samples_NNS from_IN the_DT pharmacokinetic_JJ studies_NNS described_VBD above_IN were_VBD extracted_VBN with_IN acetonitrile_NN and_CC analyzed_VBD by_IN LC-MS/_NP MS_NP to_TO identify_VB additional_JJ metabolites_NNS in_IN the_DT serum_NN ._SENT In_IN a_DT separate_JJ experiment_NN ,_, test_NN compounds_NNS (_( 10_CD muM_NN )_) were_VBD incubated_VBN with_IN mouse_NN ,_, rat_NN ,_, and_CC human_JJ liver_NN microsomes_NNS as_RB described_VBD above_IN at_IN 37_CD C_NN for_IN 20_CD min_NN ,_, and_CC the_DT resulting_VBG samples_NNS were_VBD extracted_VBN before_IN being_VBG analyzed_VBN for_IN metabolites_NNS ._SENT Protection_NN from_IN infection_NN in_IN the_DT mouse_NN septicemia_NN model_NN (_( S._NP aureus_NN strain_NN Smith_NP )_) ._SENT |_SYM A_DT standard_JJ peritonitis_NN model_NN of_IN infection_NN was_VBD used_VBN as_IN an_DT initial_JJ screen_NN to_TO determine_VB the_DT relative_JJ efficacies_NNS of_IN the_DT PDF_NP inhibitors_NNS (_( MDS_NP Pharma_NP Services_NP ,_, Bothell_NP ,_, Wash._NP )_) ._SENT Briefly_RB ,_, outbred_VBD ICR-derived_JJ mice_NNS (_( 20_CD to_TO 25_CD g_NN each_DT )_) were_VBD inoculated_VBN intraperitoneally_RB with_IN a_DT 90_CD to_TO 100_CD %_NN lethal_JJ dose_NN (_( 9.0_CD x_SYM 105_CD CFU/mouse_NN )_) of_IN S._NP aureus_NN strain_NN Smith_NP (_( ATCC_NP 19636_CD )_) in_IN 0.5_CD ml_NN of_IN brain_NN heart_NN infusion_NN broth_NN containing_VBG 5_CD %_NN mucin_NN ._SENT Compounds_NNS were_VBD dissolved_VBN in_IN 20_CD %_NN cyclodextrin_NN and_CC administered_VBN subcutaneously_RB (_( s.c._NP )_) and/or_CC p.o._NP at_IN 1_CD and_CC 5_CD h_NN after_IN infection_NN ._SENT Vancomycin_NP was_VBD included_VBN as_IN a_DT control_NN antibiotic_NN ,_, and_CC animals_NNS in_IN this_DT antibiotic_JJ regimen_NN were_VBD dosed_VBN s.c._JJ Groups_NNS of_IN five_CD mice_NNS were_VBD used_VBN for_IN each_DT dose_NN level_NN ._SENT Mice_NNS were_VBD monitored_VBN daily_RB for_IN 6_CD days_NNS ,_, and_CC cumulative_JJ mortality_NN was_VBD used_VBN to_TO determine_VB the_DT 50_CD %_NN effective_JJ dose_NN (_( ED50_NP )_) by_IN nonlinear_JJ regression_NN with_IN Graph-Pad_NP Prism_NP (_( Graph_NP Pad_NP Software_NP )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Synthesis_NP of_IN N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS ._SENT Synthesis_NN of_IN N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS ._SENT The_DT letters_NNS in_IN the_DT scheme_NN represent_VBP the_DT following_VBG solvents_NNS :_: a_DT ,_, NsCl_NP ,_, aqueous_JJ NaHCO3_NP ,_, DCM_NP ;_: b_LS ,_, R1OH_NP ,_, DIAD_NP ,_, PPh3_NP ;_: c_LS ,_, PhSH_NP ,_, TBDE-PS_NP ,_, DMF_NP ;_: d_LS ,_, COCl2_NP ,_, aqueous_JJ NaHCO3_NP ,_, Et2O_NP ;_: e_LS ,_, l-Pro-OtBu_NP ,_, pyridine_NN ,_, DCM_NP ;_: f_LS ,_, TFA_NP ,_, DCM_NP ;_: g_NN ,_, R2NH2_NP ,_, PyBop_NP ,_, DIEA_NP ,_, DMF_NP ;_: and_CC h_NN ,_, aqueous_JJ NH2OH_NP ,_, dioxane_NN ._SENT Previously_RB ,_, the_DT alkyl_NN succinate_NN hydroxamic_JJ acid_NN VRC3324_NP ,_, (2R)-butyl-N4-hydroxy-N1-[2-methyl-(1S)-(naphthalen-2-ylcarbamoyl)-propyl]-succinamide_NN ,_, was_VBD identified_VBN as_IN a_DT potent_JJ PDF_NN inhibitor_NN with_IN excellent_JJ antibacterial_NN activity_NN (_( C._NP Hackbarth_NP ,_, S._NP Lopez_NP ,_, M._NP Gomez_NP ,_, W._NP Wang_NP ,_, J._NP Jacobs_NP ,_, R._NP Jain_NP ,_, Z.-J_NP ._SENT Ni_NP ,_, J._NP Trias_NP ,_, D._NP Chen_NP ,_, G._NP Withers_NP ,_, K._NP Clark_NP ,_, J._NP Koehn_NP ,_, B._NP Weidmann_NP ,_, D._NP Patel_NP ,_, and_CC Z._NP Yuan_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 2173_CD ,_, 2000_CD )_) ._SENT Similar_JJ compounds_NNS of_IN this_DT chemical_JJ class_NN exhibit_NN broad-spectrum_NN antibacterial_NN activity_NN and_CC in_IN vivo_JJ activity_NN in_IN a_DT mouse_NN septicemia_NN model_NN (_( D._NP Chen_NP ,_, C._NP Hackbarth_NP ,_, Z.-J_NP ._SENT Ni_NP ,_, W._NP Wang_NP ,_, C._NP Wu_NP ,_, D._NP Young_NP ,_, R._NP White_NP ,_, J._NP Trias_NP ,_, D._NP Patel_NP ,_, and_CC Z._NP Yuan_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 2175_CD ,_, 2000_CD )_) ._SENT In_IN our_PP$ efforts_NNS to_TO discover_VB new_JJ pharmacophores_NNS that_WDT would_MD improve_VB the_DT biological_JJ properties_NNS of_IN this_DT class_NN of_IN inhibitors_NNS ,_, N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS were_VBD identified_VBN ._SENT VRC3852_NP represents_VBZ an_DT early_JJ lead_NN in_IN this_DT new_JJ class_NN of_IN PDF_NP inhibitors_NNS (_( Lewis_NP et_FW al._FW ,_, 41st_NP ICAAC_NP )_) ._SENT Analogs_NNS of_IN VRC3852_NP ,_, prepared_VBN in_IN both_DT library_NN format_NN and_CC as_IN individual_JJ compounds_NNS ,_, were_VBD screened_VBN to_TO identify_VB those_DT with_IN optimized_VBN activity_NN and_CC structure_NN ._SENT In_IN vitro_NN activity_NN tests_NNS ._SENT |_SYM From_IN more_JJR than_IN 200_CD analogs_NNS tested_VBN ,_, 21_CD compounds_NNS were_VBD purified_VBN by_IN high-pressure_JJ liquid_JJ chromatography_NN and_CC subjected_VBN to_TO additional_JJ biological_JJ characterization_NN ._SENT All_DT of_IN these_DT compounds_NNS were_VBD tested_VBN for_IN the_DT inhibition_NN of_IN deformylase_NN activity_NN with_IN the_DT E._NP coli_NNS and_CC S._NP pneumonia_NN enzymes_NNS overproduced_VBN and_CC purified_VBN from_IN E._NP coli_NNS ._SENT In_IN addition_NN ,_, whole-cell_NN activity_NN was_VBD assessed_VBN with_IN broth_NN microdilution_NN MICs_NN against_IN a_DT panel_NN of_IN 26_CD organisms_NNS ,_, including_VBG both_DT gram-positive_JJ and_CC -negative_JJ bacteria_NNS and_CC Candidaalbicans_NP ._SENT Twenty_CD of_IN these_DT 21_CD compounds_NNS have_VBP IC50s_NNS of_IN <=100_JJ nM_NN for_IN E._NP coli_NNS deformylase_NN ._SENT Eighteen_CD of_IN these_DT 20_CD compounds_NNS also_RB have_VBP excellent_JJ activity_NN (_( IC50s_NP ,_, <=75_NN nM_NN )_) against_IN S._NP pneumoniae_NP PDF_NP ._SENT These_DT IC50s_NP corresponded_VBD to_TO improved_VBN activity_NN against_IN S._NP pneumoniae_NNS ._SENT In_IN fact_NN ,_, the_DT two_CD compounds_NNS with_IN poor_JJ IC50s_NNS for_IN the_DT S._NP pneumoniae_NNS enzyme_NN ,_, VRC4347_NP and_CC VRC4390_NP ,_, also_RB lacked_VBD whole-cell_NN activity_NN against_IN this_DT organism_NN ,_, providing_VBG further_JJR evidence_NN that_IN this_DT class_NN of_IN compounds_NNS targets_NNS deformylase_NN for_IN the_DT inhibition_NN of_IN bacterial_JJ growth_NN ._SENT Compared_VBN with_IN the_DT MICs_NP of_IN the_DT initial_JJ lead_NN in_IN this_DT series_NN ,_, VRC3852_NP ,_, the_DT MICs_NP against_IN the_DT three_CD gram-positive_JJ pathogens_NNS tested_VBN (_( S._NP aureus_NN ,_, S._NP pneumoniae_NNS ,_, and_CC Enterococcusfaecium_NN )_) improved_VBN for_IN the_DT majority_NN of_IN the_DT compounds_NNS listed_VBD ._SENT One_CD of_IN the_DT compounds_NNS that_WDT had_VBD poor_JJ gram-positive_JJ activity_NN ,_, VRC4390_NP ,_, nonetheless_RB maintained_VBD its_PP$ activity_NN against_IN H._NP influenzae_NP ._SENT On_IN the_DT other_JJ hand_NN ,_, VRC4234_NP and_CC VRC4305_NP were_VBD more_RBR active_JJ against_IN S._NP aureus_NN and_CC S._NP pneumoniae_NNS but_CC less_RBR potent_JJ against_IN the_DT gram-negative_JJ pathogen_NN H._NP influenzae_NP ._SENT Apparently_RB ,_, these_DT compounds_NNS readily_RB undergo_VBP efflux_NN in_IN E._NP coli_NNS ,_, since_IN none_NN was_VBD active_JJ against_IN wild-type_JJ E._NP coli_NNS but_CC all_DT possessed_JJ low_JJ MICs_NN against_IN an_DT E._NP coliacr_NN mutant_NN which_WDT lacks_VBZ the_DT Acr_NP efflux_NN pump_NN ._SENT None_NN of_IN these_DT compounds_NNS was_VBD active_JJ against_IN C._NP albicans_NNS ._SENT To_TO determine_VB whether_IN this_DT class_NN of_IN compounds_NNS inhibited_VBD bacterial_JJ growth_NN through_IN the_DT inhibition_NN of_IN deformylase_NN ,_, each_DT of_IN the_DT compounds_NNS was_VBD tested_VBN for_IN its_PP$ ability_NN to_TO inhibit_VB the_DT growth_NN of_IN an_DT actinonin-resistant_JJ S._NP aureus_NN strain_NN ,_, VSAU6011_NP ._SENT This_DT strain_NN harbors_VBZ a_DT loss-of-function_NN mutation_NN in_IN the_DT formyltransferase-encoding_JJ gene_NN ,_, bypassing_VBG the_DT need_NN for_IN deformylase_NN activity_NN and_CC permitting_VBG growth_NN even_RB when_WRB PDF_NP activity_NN is_VBZ inhibited_VBN ._SENT S._NP aureus_NN VSAU6011_NP was_VBD highly_RB resistant_JJ to_TO all_DT of_IN the_DT compounds_NNS tested_VBD ,_, demonstrating_VBG that_IN N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS ,_, like_IN alkyl_NN succinates_NNS ,_, inhibit_VBP bacterial_JJ growth_NN through_IN the_DT inhibition_NN of_IN deformylase_NN ._SENT These_DT compounds_NNS were_VBD also_RB tested_VBN for_IN their_PP$ potential_JJ cytotoxicity_NN and_CC inhibition_NN of_IN matrilysin_NN ,_, a_DT member_NN of_IN the_DT mammalian_JJ MMP_NP superfamily_NN which_WDT closely_RB resembles_VBZ PDF_NN ._SENT Matrilysin_NP activity_NN was_VBD not_RB inhibited_VBN in_IN the_DT presence_NN of_IN up_RB to_TO and_CC in_IN most_JJS instances_NNS exceeding_VBG 100_CD muM_NN PDF_NN inhibitor_NN ._SENT In_IN addition_NN ,_, the_DT IC50s_NP of_IN VRC4232_NP and_CC VRC4307_JJ against_IN human_JJ ACE_NNS ,_, another_DT metalloprotease_NN ,_, were_VBD higher_JJR than_IN 100_CD muM_NN ._SENT Thus_RB ,_, these_DT N-alkyl_NP urea_NN hydroxamic_JJ acids_NNS are_VBP over_IN 1,000_CD times_NNS more_RBR potent_JJ against_IN bacterial_JJ deformylase_NN than_IN the_DT eukaryotic_JJ metalloenzymes_NNS tested_VBD ._SENT When_WRB these_DT compounds_NNS were_VBD tested_VBN against_IN two_CD different_JJ mammalian_JJ cell_NN lines_NNS ,_, the_DT IC50s_NP ,_, determined_VBN after_IN 72_CD h_NN of_IN continuous_JJ exposure_NN ,_, were_VBD at_IN least_JJS 10-fold_JJ higher_JJR than_IN the_DT MICs_NP for_IN the_DT major_JJ bacterial_JJ pathogens_NNS in_IN the_DT screening_NN panel_NN ._SENT A_DT closer_JJR examination_NN of_IN the_DT structure-activity_NN relationships_NNS of_IN these_DT compounds_NNS (_( see_VB Discussion_NP )_) suggested_VBD that_IN the_DT cytotoxicity_NN of_IN these_DT compounds_NNS generally_RB correlated_VBN with_IN their_PP$ hydrophobicity_NN ._SENT Given_VBN their_PP$ overall_NN in_IN vitro_NN profiles_NNS ,_, VRC4232_NP and_CC VRC4307_NP were_VBD selected_VBN as_IN new_JJ leads_NNS for_IN additional_JJ in_IN vitro_NN and_CC in_IN vivo_JJ characterizations_NNS ._SENT X-ray_NN analysis_NN of_IN binding_JJ interactions_NNS ._SENT |_SYM Key_JJ parameters_NNS and_CC summary_NN statistics_NNS for_IN the_DT refined_JJ PDF_NN model_NN are_VBP provided_VBN in_IN Table_NP ._SENT After_IN independent_JJ rigid-body_JJ refinement_NN of_IN the_DT three_CD PDF_NN proteins_NNS in_IN the_DT asymmetric_JJ unit_NN ,_, the_DT electron_NN density_NN for_IN the_DT three_CD inhibitors_NNS was_VBD clearly_RB seen_VBN in_IN each_DT of_IN the_DT active_JJ sites_NNS ._SENT Several_JJ rounds_NNS of_IN iterative_JJ model_NN building_NN (_( including_VBG the_DT addition_NN of_IN water_NN molecules_NNS and_CC correcting_VBG loops_NNS involved_VBN in_IN crystal_NN contacts_NNS )_) with_IN the_DT program_NN O_NN and_CC refinement_NN were_VBD conducted_VBN before_IN the_DT three_CD inhibitor_NN molecules_NNS were_VBD added_VBN to_TO the_DT model_NN ._SENT In_IN complex_JJ A_NP ,_, the_DT inhibitor_NN could_MD be_VB positioned_VBN unambiguously_RB in_IN the_DT electron_NN density_NN ._SENT For_IN complexes_NNS B_NP and_CC C_NP ,_, there_EX was_VBD a_DT weak_JJ ,_, broken_VBN electron_NN density_NN for_IN the_DT 4,5-dimethylthiazole_JJ ring_NN of_IN the_DT inhibitor_NN ._SENT Rfree_NP was_VBD monitored_VBN while_IN additional_JJ water_NN molecules_NNS were_VBD added_VBN ._SENT The_DT final_JJ model_NN contained_VBD three_CD PDF-compound_NN VRC4307_JJ complexes_NNS as_RB well_RB as_IN 435_CD water_NN ,_, 3_CD sulfate_NN ,_, and_CC 5_CD glycerol_NN molecules_NNS ,_, resulting_VBG in_IN an_DT R_NN factor_NN of_IN 18.6_CD %_NN (_( Rfree_NP =_SYM 21.6_CD %_NN )_) in_IN the_DT resolution_NN range_NN of_IN 30.0_CD to_TO 1.8_CD A._NP The_DT structure_NN of_IN E._NP coli_NNS PDF_NN has_VBZ already_RB been_VBN extensively_RB characterized_VBN and_CC will_MD not_RB be_VB elaborated_VBN on_IN further_RBR here_RB ._SENT When_WRB the_DT PDF_NN structure_NN with_IN bound_VBN VRC4307_JJ is_VBZ examined_VBN ,_, the_DT hydroxamic_JJ acid_NN is_VBZ observed_VBN to_TO coordinate_VB the_DT active-site_JJ Ni2+_NP ,_, as_RB expected_VBN ;_: the_DT cyclopentyl_NN ring_NN system_NN of_IN VRC4307_JJ lies_NNS in_IN the_DT S1_NP '_POS pocket_NN of_IN the_DT enzyme_NN ._SENT The_DT carbonyl_NN oxygen_NN of_IN the_DT proline_NN group_NN of_IN VRC4307_JJ forms_NNS a_DT hydrogen_NN bond_NN with_IN the_DT backbone_NN nitrogen_NN of_IN Ile44_NP ,_, maintaining_VBG the_DT peptidic_JJ interaction_NN observed_VBN for_IN the_DT PDF_NP structure_NN with_IN the_DT bound_JJ product_NN MAS_NN ._SENT Details_NNS of_IN the_DT metal_NN coordination_NN ,_, hydrogen_NN bonding_VBG ,_, and_CC Van_NP der_NP Waals_NP interactions_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT The_DT electron_NN density_NN for_IN most_JJS of_IN the_DT compound_NN is_VBZ clear_JJ and_CC unambiguous_JJ ._SENT The_DT electron_NN density_NN for_IN the_DT amide-dimethylthiazole_NN (_( Fig._NN ,_, green_JJ atoms_NNS )_) portion_NN of_IN the_DT inhibitor_NN is_VBZ weak_JJ and_CC broken_VBN ._SENT Apparently_RB ,_, the_DT inhibitor_NN is_VBZ able_JJ to_TO adopt_VB multiple_JJ conformations_NNS when_WRB bound_VBN ;_: this_DT hypothesis_NN is_VBZ illustrated_VBN by_IN superimposition_NN of_IN the_DT three_CD complexes_NNS ._SENT Surprisingly_RB ,_, the_DT peptidic_JJ interaction_NN with_IN the_DT backbone_NN carbonyl_NN of_IN Glu42_NP is_VBZ seen_VBN in_IN only_RB one_CD of_IN the_DT three_CD complexes_NNS ._SENT The_DT hydroxamic_JJ acid-metal_JJ coordination_NN in_IN the_DT PDF-VRC4307_JJ complex_NN maintains_VBZ a_DT tetrahedral_JJ configuration_NN ._SENT Although_IN the_DT overall_JJ arrangement_NN of_IN the_DT ligand_NN atoms_NNS approximates_VBZ a_DT distorted_JJ trigonal_JJ bipyrimidal_JJ geometry_NN ,_, the_DT carbonyl_NN oxygen_NN of_IN the_DT inhibitor_NN is_VBZ more_RBR distant_JJ from_IN the_DT metal_NN than_IN is_VBZ typically_RB observed_VBN in_IN metal-ligand_NN complexes_NNS ._SENT In_IN all_DT three_CD complexes_NNS ,_, the_DT Ni2+_NP distances_NNS are_VBP reasonable_JJ for_IN the_DT N_NP and_CC O_NP atoms_NNS (_( 2.0_CD to_TO 2.1_CD A_NP )_) and_CC for_IN the_DT S_NP atoms_NNS (_( 2.3_CD A_NP )_) ;_: however_RB ,_, the_DT carbonyl_NN O_NN atom_NN of_IN VRC4307_JJ is_VBZ 2.7_CD to_TO 3.0_CD A_DT from_IN the_DT metal_NN ._SENT This_DT suboptimal_JJ interaction_NN may_MD be_VB offset_VBN ,_, in_IN part_NN ,_, by_IN an_DT ideal_JJ hydrogen_NN bonding_VBG interaction_NN distance_NN between_IN the_DT c_NN 